M'zaka zaposachedwa, chithandizo cha kunenepa kwambiri komanso matenda amtundu wa 2 chasintha kwambiri. Kutsatira GLP-1 receptor agonists (mwachitsanzo, Semaglutide) ndi awiri agonists (mwachitsanzo, Tirzepatide),Retatrutide(LY3437943), aagonist atatu(GLP-1, GIP, ndi ma glucagon receptors), awonetsa mphamvu zomwe sizinachitikepo. Ndi zotsatira zochititsa chidwi pakuchepetsa thupi komanso kusintha kagayidwe kachakudya, imawonedwa ngati chithandizo chothandizira matenda a metabolic.
Njira Yochitira
-
GLP-1 receptor activation: Imawonjezera katulutsidwe ka insulini, imachepetsa chilakolako cha chakudya, imachepetsa kutuluka m'mimba.
-
GIP receptor activation: Imawonjezera kutsitsa kwa GLP-1, imakulitsa chidwi cha insulin.
-
Glucagon receptor activation: Imalimbikitsa kugwiritsa ntchito mphamvu ndi mafuta metabolism.
Synergy ya ma receptor atatu awa imalola Retatrutide kupitilira mankhwala omwe alipo pakuchepetsa thupi komanso kuwongolera glycemic.
Zoyeserera Zachipatala (Gawo II)
Mu aKuyesedwa kwa Phase II ndi odwala 338 onenepa kwambiri / onenepa kwambiri, Retatrutide inasonyeza zotsatira zabwino kwambiri.
Table: Kuyerekeza kwa Retatrutide vs. Placebo
| Mlingo (mg/sabata) | Kuchepetsa Kunenepa Kwambiri (%) | Kuchepetsa HbA1c (%) | Zochitika Zoyipa Zodziwika |
|---|---|---|---|
| 1 mg pa | -7.2% | -0.9% | Mseru, kusanza pang'ono |
| 4 mg pa | -12.9% | -1.5% | Mseru, kusowa chilakolako |
| 8 mg pa | -17.3% | -2.0% | Kusapeza bwino kwa GI, kutsekula m'mimba pang'ono |
| 12 mg pa | -24.2% | -2.2% | Mseru, kutaya chilakolako, kudzimbidwa |
| Malo | -2.1% | -0.2% | Palibe kusintha kwakukulu |
Kuwona kwa Data (Kuyerekeza Kuchepetsa Kunenepa)
Tsamba lotsatirali likuwonetsakuchepetsa kulemera kwapakatipamitundu yosiyanasiyana ya Retatrutide poyerekeza ndi placebo:
Nthawi yotumiza: Sep-16-2025